Skip to main content
. 2017 Jan 24;61(2):e02071-16. doi: 10.1128/AAC.02071-16

TABLE 2.

In vitro susceptibilities of original strains of E. coli and E. coli transconjugants expressing VIM-1 and/or KPC-2 (Etest, EUCAST)

Antibiotic MIC (μg/ml)
Original strains
 Transconjugants
40 (VIM-1/KPC-2)a 71 (VIM-1/KPC-2)b J53c J53 40T3 (KPC-2)d J53 40T5 (VIM-1/KPC-2)e J53 71T1 (VIM-1)f J53 71T3 (VIM-1/KPC-2)g
Cefoxitin >256 >256 2 8 256 256 64
Cefotaxime 32 24 0.094 0.75 16 16 64
Ceftazidime 256 96 0.125 1 64 64 96
Imipenem 4 24 0.19 1.5 3 1 12
Meropenem 4 32 0.023 0.75 0.5 0.25 8
Ertapenem 6 12 0.008 0.38 0.38 0.64 4
Aztreonam 16 128 0.064 12 16 0.25 256
Ciprofloxacin >32 >32 0.064 0.047 0.064 0.064 0.064
Gentamicin >32 >32 0.25 0.25 1 2 2
Amikacin 3 3 1 1 1.5 1.5 1.5
Tobramycin 16 12 0.125 0.125 3 3 3
Colistin 0.25 0.125 0.125 0.25 0.125 0.19 0.25
a

E. coli strain 40 isolated from a yellow-legged gull.

b

E. coli strain 71 isolated from a yellow-legged gull.

c

Sodium azide-resistant E. coli J53 strain used as a recipient in the conjugation experiment.

d

E. coli transconjugant obtained from strains 40 and J53 that received only blaKPC-2.

e

E. coli transconjugant obtained from strains 40 and J53 that received both blaKPC-2 and blaVIM-1.

f

E. coli transconjugant obtained from strains 71 and J53 that received only blaVIM-1.

g

E. coli transconjugant obtained from strains 71 and J53 that received both blaKPC-2 and blaVIM-1.